Dr Anthony Kong Academics Reader and Honorary Consultant Clinical Oncologist Contact details +44 (0) 20 7848 8302 anthony.kong@kcl.ac.uk
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study Harrington, K. J., Kong, A., Mach, N., Chesney, J. A., Fernandez, B. C., Rischin, D., Cohen, E. E. W., Radcliffe, H-S., Gumuscu, B., Cheng, J., Snyder, W. & Siu, L. L., 15 Jul 2020, In : Clinical cancer research : an official journal of the American Association for Cancer Research. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1158/1078-0432.CCR-20-1170 Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: The WISTERIA trial protocol Kong, A., Good, J., Kirkham, A., Savage, J., Mant, R., Llewellyn, L., Parish, J., Spruce, R., Forster, M., Schipani, S., Harrington, K., Sacco, J., Murray, P., Middleton, G., Yap, C. & Mehanna, H., 16 Mar 2020, In : BMJ Open. 10, 3, e033009. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1136/bmjopen-2019-033009 Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial Jones, D. A., Mistry, P., Dalby, M., Fulton-Lieuw, T., Kong, A. H., Dunn, J., Mehanna, H. M. & Gray, A. M., Jan 2020, In : European Journal of Cancer. 124, p. 178-185 8 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.ejca.2019.10.025 Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer Mumin, N. H., Drobnitzky, N., Patel, A., Lourenco, L. M., Cahill, F. F., Jiang, Y., Kong, A. & Ryan, A. J., 24 Jan 2019, In : BMC Cancer. 19, 1, 102. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1186/s12885-019-5295-z Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, M., Dalby, M., Mistry, P. & Sen, M., 5 Jan 2019, In : Lancet. 393, 10166, p. 51-60 10 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/S0140-6736(18)32752-1 Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck Golusinski, P., Di Maio, P., Pehlivan, B., Colley, S., Nankivell, P., Kong, A., Hartley, A. & Mehanna, H., 30 Nov 2018, In : ORAL ONCOLOGY. 88, p. 145-152 8 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.oraloncology.2018.11.020 Should we de-escalate treatment for HPV positive oropharyngeal head and neck cancer? Mehanna, H., Bryant, J. & Kong, A., 24 Nov 2018, Critical Issues in Head and Neck Oncology. Vermorken, J., Budach, V., Leemans, C., Machiels, J-P., Nicolai, P. & O'Sullivan, B. (eds.). SPRINGER, p. 165-170 6 p. Research output: Chapter in Book/Report/Conference proceeding - Chapter. DOIs: https://doi.org/10.1007/978-3-319-98854-2 Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma Payne, K., Spruce, R., Beggs, A., Sharma, N., Kong, A., Martin, T., Parmar, S., Praveen, P., Nankivell, P. & Mehanna, H., 1 Jul 2018, In : Head and Neck. 40, 7, p. 1598-1604 7 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1002/hed.25140 Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN) Vigneswara, V. & Kong, A., Apr 2018, In : Annals of Oncology. 29, 4, p. 794-796 3 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1093/annonc/mdy065 Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen Kong, A., Rea, D., Ahmed, S., Beck, J. T., López, R. L., Biganzoli, L., Armstrong, A. C., Aglietta, M., Alba, E., Campone, M., Schmitz, S-F. H., Lefebvre, C., Akimov, M. & Lee, S-C., 25 Apr 2016, In : Oncotarget. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.18632/oncotarget.8974 View all publications